Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator von Lewis, Hal A, Buchanan, Sean G, Burley, Stephen K, Conners, Kris, Dickey, Mark, Dorwart, Michael, Fowler, Richard, Gao, Xia, Guggino, William B, Hendrickson, Wayne A, Hunt, John F, Kearins, Margaret C, Lorimer, Don, Maloney, Peter C, Post, Kai W, Rajashankar, Kanagalaghatta R, Rutter, Marc E, Sauder, J Michael, Shriver, Stephanie, Thibodeau, Patrick H, Thomas, Philip J, Zhang, Marie, Zhao, Xun, Emtage, Spencer

Volltext

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo von Buchanan, Sean G, Hendle, Jorg, Lee, Patrick S, Smith, Christopher R, Bounaud, Pierre-Yves, Jessen, Katti A, Tang, Crystal M, Huser, Nanni H, Felce, Jeremy D, Froning, Karen J, Peterman, Marshall C, Aubol, Brandon E, Gessert, Steve F, Sauder, J Michael, Schwinn, Kenneth D, Russell, Marijane, Rooney, Isabelle A, Adams, Jason, Leon, Barbara C, Do, Tuan H, Blaney, Jeff M, Sprengeler, Paul A, Thompson, Devon A, Smyth, Lydia, Pelletier, Laura A, Atwell, Shane, Holme, Kevin, Wasserman, Stephen R, Emtage, Spencer, Burley, Stephen K, Reich, Siegfried H

Volltext

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer von Wander, Seth A, Cohen, Ofir, Gong, Xueqian, Johnson, Gabriela N, Buendia-Buendia, Jorge E, Lloyd, Maxwell R, Kim, Dewey, Luo, Flora, Mao, Pingping, Helvie, Karla, Kowalski, Kailey J, Nayar, Utthara, Waks, Adrienne G, Parsons, Stephen H, Martinez, Ricardo, Litchfield, Lacey M, Ye, Xiang S, Yu, Chunping, Jansen, Valerie M, Stille, John R, Smith, Patricia S, Oakley, Gerard J, Chu, Quincy S, Batist, Gerald, Hughes, Melissa E, Kremer, Jill D, Garraway, Levi A, Winer, Eric P, Tolaney, Sara M, Lin, Nancy U, Buchanan, Sean G, Wagle, Nikhil

Volltext

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib von Gong, Xueqian, Litchfield, Lacey M., Webster, Yue, Chio, Li-Chun, Wong, Swee Seong, Stewart, Trent R., Dowless, Michele, Dempsey, Jack, Zeng, Yi, Torres, Raquel, Boehnke, Karsten, Mur, Cecilia, Marugán, Carlos, Baquero, Carmen, Yu, Chunping, Bray, Steven M., Wulur, Isabella H., Bi, Chen, Chu, Shaoyou, Qian, Hui-Rong, Iversen, Philip W., Merzoug, Farhana F., Ye, Xiang S., Reinhard, Christoph, De Dios, Alfonso, Du, Jian, Caldwell, Charles W., Lallena, María José, Beckmann, Richard P., Buchanan, Sean G.

Volltext

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene von Gong, Xueqian, Du, Jian, Parsons, Stephen H, Merzoug, Farhana F, Webster, Yue, Iversen, Philip W, Chio, Li-Chun, Van Horn, Robert D, Lin, Xi, Blosser, Wayne, Han, Bomie, Jin, Shaoling, Yao, Sufang, Bian, Huimin, Ficklin, Chris, Fan, Li, Kapoor, Avnish, Antonysamy, Stephen, Mc Nulty, Ann M, Froning, Karen, Manglicmot, Danalyn, Pustilnik, Anna, Weichert, Kenneth, Wasserman, Stephen R, Dowless, Michele, Marugán, Carlos, Baquero, Carmen, Lallena, María José, Eastman, Scott W, Hui, Yu-Hua, Dieter, Matthew Z, Doman, Thompson, Chu, Shaoyou, Qian, Hui-Rong, Ye, Xiang S, Barda, David A, Plowman, Gregory D, Reinhard, Christoph, Campbell, Robert M, Henry, James R, Buchanan, Sean G

Volltext

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation von Yadav, Vipin, Burke, Teresa F, Huber, Lysiane, Van Horn, Robert D, Zhang, Youyan, Buchanan, Sean G, Chan, Edward M, Starling, James J, Beckmann, Richard P, Peng, Sheng-Bin

Volltext

A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase von Atwell, Shane, Adams, Jason M., Badger, John, Buchanan, Michelle D., Feil, Ingeborg K., Froning, Karen J., Gao, Xia, Hendle, Jörg, Keegan, Kevin, Leon, Barbara C., Müller-Dieckmann, Hans J., Nienaber, Vicki L., Noland, Brian W., Post, Kai, Rajashankar, K.R., Ramos, Aurora, Russell, Marijane, Burley, Stephen K., Buchanan, Sean G.

Volltext

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy von Du, Jian, Yan, Lei, Torres, Raquel, Gong, Xueqian, Bian, Huimin, Marugán, Carlos, Boehnke, Karsten, Baquero, Carmen, Hui, Yu-Hua, Chapman, Sonya C, Yang, Yanzhu, Zeng, Yi, Bogner, Sarah M, Foreman, Robert T, Capen, Andrew, Donoho, Gregory P, Van Horn, Robert D, Barnard, Darlene S, Dempsey, Jack A, Beckmann, Richard P, Marshall, Mark S, Chio, Li-Chun, Qian, Yuewei, Webster, Yue W, Aggarwal, Amit, Chu, Shaoyou, Bhattachar, Shobha, Stancato, Louis F, Dowless, Michele S, Iversen, Phillip W, Manro, Jason R, Walgren, Jennie L, Halstead, Bartley W, Dieter, Matthew Z, Martinez, Ricardo, Bhagwat, Shripad V, Kreklau, Emiko L, Lallena, Maria Jose, Ye, Xiang S, Patel, Bharvin K R, Reinhard, Christoph, Plowman, Gregory D, Barda, David A, Henry, James R, Buchanan, Sean G, Campbell, Robert M

Volltext

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft mo... von Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.

Volltext

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders von Wu, Xuewei, Yang, Xiaobao, Xiong, Yan, Li, Ruitong, Ito, Takahiro, Ahmed, Tamer A, Karoulia, Zoi, Adamopoulos, Christos, Wang, Hong, Wang, Li, Xie, Ling, Liu, Jing, Ueberheide, Beatrix, Aaronson, Stuart A, Chen, Xian, Buchanan, Sean G, Sellers, William R, Jin, Jian, Poulikakos, Poulikos I

Volltext

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells von Litchfield, Lacey M, Boehnke, Karsten, Brahmachary, Manisha, Mur, Cecilia, Bi, Chen, Stephens, Jennifer R, Sauder, J Michael, Gutiérrez, Sonia M, McNulty, Ann M, Ye, Xiang S, Wu, Wenjuan, Lallena, María José, Gong, Xueqian, Merzoug, Farhana F, Jansen, Valerie M, Buchanan, Sean G

Volltext

MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor―Dependent Fashion to Suppress Carcinoma Growth von ZHANG, Yu-Wen, STAAL, Ben, VANDE WOUDE, George F, ESSENBURG, Curt, YANLI SU, LIANG KANG, WEST, Rich, KAUFMAN, Dafna, DEKONING, Tom, EAGLESON, Bryn, BUCHANAN, Sean G

Volltext

Unraveling the genomic determinants of response to CDK4/6 inhibitors von Litchfield, Lacey M, Webster, Vue W, Buchanan, Sean G

Volltext

Structural Studies of Salmonella typhimurium ArnB (PmrH) Aminotransferase : A 4-Amino-4-Deoxy-L-Arabinose Lipopolysaccharide-Modifying Enzyme von Noland, Brian W., Newman, Janet M., Hendle, Jörg, Badger, John, Christopher, Jon A., Tresser, Jason, Buchanan, Michelle D., Wright, Tobi A., Rutter, Marc E., Sanderson, Wendy E., Müller-Dieckmann, Hans-Joachim, Gajiwala, Ketan S., Buchanan, Sean G.

Volltext

A Novel Antibody-Drug Conjugate Targeting CCR7 in Hematologic Malignancies von Dang, Anhthu, Knee, Deborah, Wang, Cui Ying, Gao, Feng, Liu, Guoxun, Briones, Sergio, Coulson, Michelle, Makofske, Jessica, Mansfield, Keith, Liu, May, Mulvey, Tanya, Meseck, Emily K, Woolfenden, Steve, Buchanan, Sean G, Steensma, David, Askoxylakis, Vasileios

Volltext

Abstract PR06: Combinations with CDK4/6 inhibitors to treat cancers with mutations in both KRAS and CDKN2A von Litchfield, Lacey, Kapoor, Avnish, Wu, Wenjuan, Gong, Xueqian, Webster, Yue, Peng, Sheng-Bin, Bhagwat, Shripad, Merzoug, Farhana, Buchanan, Sean G.

Volltext

Protein structure: discovering selective protein kinase inhibitors von Buchanan, Sean G.

Volltext

Abstract 3104: Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6 von Gong, Xueqian, Chio, Li-Chun, Lallena, MaryJo, Merzoug, Farhana, Chu, Shaoyou, Webster, Yue, Dempsey, Jack, Ma, Xiwen, De Dios, Alfonso, Beckman, Richard, Buchanan, Sean G.

Volltext

Abstract A07: The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib von Xueqian, Gong, Chio, Li-Chun, Webster, Yue, Lallena, Maria Jose, Boehnke, Karsten, Torres, Raquel, Iversen, Phil, Dios, Alfonso De, Smith, Ian, Reinhard, Christoph, Peng, Sheng-Bin, Dempsey, Jack, Burke, Teresa, Chen, Shih-Hsun, Stewart, Trent, Beckmann, Richard, Wu, Wenjuan, Buchanan, Sean G.

Volltext

Abstract A104: A screening method for the identification of potentially effective drug-drug combinations reveals a synergistic interaction between Aurora-A inhibitor MK-5108 and Bc... von Gong, Xueqian, Jin, Shaoling, Merzoug, Farhana, Ye, Xiang S., Lallena, MaryJo, Du, Jian, Webster, Yue, Ma, Xiwen, Reinhard, Christoph, Iversen, Phillip, Buchanan, Sean G.

Volltext